Larry Ellberger - Celldex Therapeutics Independent Chairman of the Board
| CLDX Stock | USD 38.53 1.10 2.78% |
Chairman
Mr. Larry Ellberger is an Independent Chairman of the Board of Celldex Therapeutics Inc. since September 2009. He was a director of Celldex since August 2003. Mr. Ellberger was formerly Chairman of the Board of Omrix BioPharmaceuticals, Inc. until its acquisition by Johnson Johnson in 2008. From 2003 to July 2012, Mr. Ellberger was Founding Partner of HVA, Inc. a consulting firm specializing in business development, product acquisition and licensing, and mergers and acquisitions for pharmaceutical, biotechnology, drug delivery, and medical device companies. From October 2005 to May 2006, Mr. Ellberger was Interim Chief Executive Officer of PDI, Inc., a provider of sales and marketing services to the biopharmaceutical industry. Previously, he was a member of the Board of Directors of PDI and Chairman of the Audit Committee. From 2000 to 2003, Mr. Ellberger was Senior Vice President of Powderject PLC, a U.K. vaccine company. He was also a member of the Board of Directors of Powderject. From 1995 to 1999, Mr. Ellberger held several positions at W.R. Grace Co. including Interim Chief Executive Officer, Chief Financial Officer and Senior Vice President, Strategic Planning and Development. From 1975 to 1995, Mr. Ellberger held numerous senior executive positions at American Cyanamid Company, serving the last four years as Vice President, Corporationrationrate Development. since 2009.
| Age | 69 |
| Tenure | 15 years |
| Address | Perryville III Building, Hampton, NJ, United States, 08827 |
| Phone | 908 200 7500 |
| Web | https://www.celldex.com |
Celldex Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.217) % which means that it has lost $0.217 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3745) %, meaning that it created substantial loss on money invested by shareholders. Celldex Therapeutics' management efficiency ratios could be used to measure how well Celldex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.34 in 2024. Return On Capital Employed is likely to drop to -0.34 in 2024. At this time, Celldex Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 453.3 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 31 M in 2024.Similar Executives
| Found 8 records | CHAIRMAN Age | ||
| Leonard Gage | Cytokinetics | 75 | |
| MPH Coles | Cerevel Therapeutics Holdings | 64 | |
| Michael Brauser | Cogent Biosciences | 58 | |
| Keith Harris | MeiraGTx Holdings PLC | 64 | |
| Wendall Wierenga | Crinetics Pharmaceuticals | 69 | |
| Jun Zhi | Dyne TherapeuticsInc | 55 | |
| Patrick Wood | Dyne TherapeuticsInc | 53 | |
| MD FACP | Edgewise Therapeutics | 64 | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.22 |
Celldex Therapeutics Leadership Team
Elected by the shareholders, the Celldex Therapeutics' board of directors comprises two types of representatives: Celldex Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celldex. The board's role is to monitor Celldex Therapeutics' management team and ensure that shareholders' interests are well served. Celldex Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celldex Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Till, Senior Communications | ||
| Prof Schlessinger, CoFounder Board | ||
| Keith Brownlie, Director | ||
| Diane MD, Senior Officer | ||
| Sam Martin, CFO, Senior Vice President | ||
| Gerald McMahon, Director | ||
| Margo MD, Senior Affairs | ||
| Sarah Cavanaugh, Vice President Investor Relations & Corporate Communications | ||
| James Marino, Director | ||
| George Elston, Independent Director | ||
| Freddy Esq, Senior Counsel | ||
| Thomas Davis, Senior Vice President Chief Medical Officer | ||
| Richard Wright, Senior Vice President Chief Commercial Officer` | ||
| Anthony MBA, President, Founder | ||
| Theresa LaVallee, Senior Vice President - Regulatory and Precision Medicine | ||
| Ronald Pepin, Chief Bus. Officer and Sr. VP | ||
| Harry Penner, Independent Director | ||
| Karen Shoos, Independent Director | ||
| Richard Broek, Director | ||
| Anthony Marucci, President CEO, Director | ||
| Diane Young, Senior Vice President Chief Medical Officer | ||
| Avery Catlin, CFO, Principal Accounting Officer, Sr. VP, Treasurer and Secretary | ||
| Elizabeth Crowley, Senior Vice President Chief Product Development Officer | ||
| Larry Ellberger, Independent Chairman of the Board | ||
| Herbert Conrad, Independent Director | ||
| Margo HeathChiozzi, Senior Vice President - Regulatory Affairs | ||
| Tibor Keler, Founder, Chief Scientific Officer and Executive VP |
Celldex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celldex Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (8.50) % | ||||
| Current Valuation | 1.73 B | ||||
| Shares Outstanding | 65.7 M | ||||
| Shares Owned By Insiders | 0.34 % | ||||
| Shares Owned By Institutions | 96.79 % | ||||
| Number Of Shares Shorted | 6.56 M | ||||
| Price To Earning | (2.21) X | ||||
| Price To Book | 6.01 X |
Pair Trading with Celldex Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celldex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celldex Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Celldex Stock
| 0.52 | MRKR | Marker Therapeutics | PairCorr |
| 0.41 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Celldex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Celldex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Celldex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Celldex Therapeutics to buy it.
The correlation of Celldex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Celldex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Celldex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Celldex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.Note that the Celldex Therapeutics information on this page should be used as a complementary analysis to other Celldex Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Celldex Stock analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is Celldex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Celldex Therapeutics. If investors know Celldex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Celldex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.92) | Revenue Per Share 0.142 | Quarterly Revenue Growth 1.561 | Return On Assets (0.22) | Return On Equity (0.37) |
The market value of Celldex Therapeutics is measured differently than its book value, which is the value of Celldex that is recorded on the company's balance sheet. Investors also form their own opinion of Celldex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Celldex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Celldex Therapeutics' market value can be influenced by many factors that don't directly affect Celldex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Celldex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Celldex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Celldex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.